Project Grant R43ES025098

This $306,872 Project Grant award from the National Institute of Environmental Health Sciences (CFDA 93.113 - Environmental Health) supports Bioprinting Laboratories Inc. in Dallas, TX to develop a high-throughput developmental neurotoxicity (DNT) testing platform using engineered brain organoids. The key products and services to be delivered include: Establishing genetically engineered, induced pluripotent stem cells with a promoter-reporter assay system on a high-throughput, pillar/perfusion...

This $437,250 Project Grant award from the National Eye Institute's Vision Research federal grant program (CFDA 93.867) aims to develop an integrated platform that combines 3D bioprinting, optogenetic stimulation, multi-electrode array (MEA) recording, and real-time fluorescence imaging to create a "visual-circuit-on-a-chip" for evaluating neural activity in stem cell-derived retinal disease models. The project, awarded to the University of California, San Diego, seeks to address...

This Project Grant award, funded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program, supports research investigating the effects of ultraviolet radiation (UVR) exposure on chromatin structure and gene expression in melanocytes, which are the origin of cutaneous malignant melanoma. The $156,250 award, granted to the University of Toledo Health Science Campus, aims to elucidate how the loss of the BRG1 chromatin remodeling...

This Cooperative Agreement award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $616,202 to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Inc., to identify and develop non-invasive biomarkers of radiation exposure in human skin. The project aims to utilize a model of irradiating human skin grafts carried by immunodeficient mice to identify and validate keratinocyte biomarkers that can discriminate between...

This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...

This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...

The National Eye Institute (NEI) awarded a $412,285 Project Grant under the Vision Research program (CFDA 93.867) to Oregon Health & Science University (OHSU) to validate an advanced transepithelial corneal collagen crosslinking (CXL) technology. The goal is to develop a more effective CXL procedure that can strengthen the cornea without requiring removal of the surface epithelium, which often leads to complications. The key products and services to be delivered include: Constructing an...

This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...

This National Science Foundation Project Grant of $495,000 will support the development of biopsy-free, label-free three-dimensional virtual histology of intact skin through March 2025. Funded under the Engineering program (CFDA 47.041), the award to the University of California, Los Angeles aims to advance a machine learning-based technique to transform 3D skin images into virtually stained images that can facilitate accurate and rapid diagnosis of skin lesions without biopsy. Specifically, the...

This Project Grant award of $2,085,765.00 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Phusis Therapeutics, Inc. for the "Clinical Evaluation of a Novel AKT/PDK1 Inhibitor, PHT-427, for the Treatment of Multi-Field Actinic Keratoses". The award period runs from September 15, 2025 to August 31, 2026. The grant will fund the clinical evaluation of PHT-427, a novel topical therapy developed by Phusis Therapeutics to treat actinic keratosis...